LEXX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lexaria Bioscience Corp (LEXX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is deteriorating, with no revenue and significant losses. Technical indicators show a bearish trend, and there are no strong trading signals or positive catalysts to support a buy decision. Analyst sentiment has also weakened with a lowered price target.
The MACD is slightly positive at 0.00687 and expanding, but RSI at 69.065 is neutral. Moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels (R1: 0.711, R2: 0.747) and near its pivot point (0.654), suggesting limited upward momentum.
NULL identified. No recent news or significant trading trends.
The company's financials are extremely poor, with revenue at $0, net income down 41.01% YoY, and EPS dropping 56.25% YoY. Analyst price target was significantly reduced from $4 to $1.50 due to underwhelming performance in a recent study.
In Q1 2026, revenue dropped to $0 (-100% YoY), net income fell to -$1,595,007 (-41.01% YoY), EPS declined to -0.07 (-56.25% YoY), and gross margin dropped to 0 (-100% YoY).
H.C. Wainwright analyst Yi Chen lowered the price target from $4 to $1.50, maintaining a Buy rating. The downgrade reflects weaker-than-expected results from a recent study, particularly in body weight reduction performance.
